Sanela Bilic
About
Sanela Bilic is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Sanela Bilic has authored 44 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 18 papers in Molecular Biology and 14 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Sanela Bilic's work include Multiple Myeloma Research and Treatments (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Sanela Bilic is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Sanela Bilic collaborates with scholars based in United States, Switzerland and Canada. Sanela Bilic's co-authors include Randi Isaacs, Nikhil C. Munshi, Johan Baeck, John Rediske, Kevin R. Kelly, Jatin J. Shah, Swaminathan P. Iyer, A. Keith Stewart, Suman Sen and Surinder Kaur and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.
In The Last Decade
Sanela Bilic
41 papers receiving 1.0k citations
Peers
Sanela Bilic
Wichai Chinratanalab United States
Shih‐Feng Cho Taiwan
Sherilyn A. Tuazon United States
Douglas W. Sborov United States
R N Sridhara United States
Gordon Moody United States
Caitlin Costello United States
Carolina Schinke United States
Rachel Kobos United States
Yvette C. Tanhehco United States
Citations per year, relative to Sanela Bilic Sanela Bilic (= 1×)
peers
Wichai Chinratanalab
Countries citing papers authored by Sanela Bilic
Since
Specialization
Citations
This map shows the geographic impact of Sanela Bilic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sanela Bilic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sanela Bilic more than expected).
Fields of papers citing papers by Sanela Bilic
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Sanela Bilic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sanela Bilic. The network helps show where Sanela Bilic may publish in the future.
Co-authorship network of co-authors of Sanela Bilic
This figure shows the co-authorship network connecting the top 25 collaborators of Sanela Bilic. A scholar is included among the top collaborators of Sanela Bilic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sanela Bilic. Sanela Bilic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Johnson, Melissa L., Timothy F. Burns, Jonathan R. Thompson, et al.. (2024). MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: Initial dose escalation results in the phase 1 KisMET-01 study.. Journal of Clinical Oncology. 42(16_suppl). 8558–8558.
2.
Crawford, Thomas O., Basil T. Darras, John Day, et al.. (2024). Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3. Neurology. 102(5). e209151–e209151.
3.
Desbois, Mélanie, Kevin C. Hart, Thomas J. Matthew, et al.. (2024). Abstract 1899: Novel combinations of aplitabart, a DR5 agonist IgM antibody, with ADCs or chemotherapeutic agents lead to robust anti-tumor responses in solid tumor models. Cancer Research. 84(6_Supplement). 1899–1899.
4.
Hanna, Glenn J., John M. Kaczmar, Dan P. Zandberg, et al.. (2023). 922P Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma. Annals of Oncology. 34. S582–S583.
5.
Konecny, G., Andrea E. Wahner Hendrickson, Boris Winterhoff, et al.. (2023). 756P First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23. Annals of Oncology. 34. S517–S517.
6.
Hannan, Natalie J., Paul A. Cohen, Sally Beard, et al.. (2021). Transcriptomic analysis of patient plasma reveals circulating miR200c as a potential biomarker for high-grade serous ovarian cancer. Gynecologic Oncology Reports. 39. 100894–100894.
7.
Barrett, D, Sanela Bilic, Yung Chyung, et al.. (2021). A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy. Advances in Therapy. 38(6). 3203–3222.
8.
Welsh, Brian T., Ryan Faucette, Sanela Bilic, et al.. (2021). Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors. International Journal of Toxicology. 40(3). 226–241.
9.
Walles, Markus, Bettina Rudolph, Thomas Wolf, et al.. (2016). New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats. Drug Metabolism and Disposition. 44(7). 897–910.
10.
Iyer, Swaminathan P., A. Keith Stewart, Jatin J. Shah, et al.. (2014). A Phase IB multicentre dose‐determination study of BHQ 880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal‐related events. British Journal of Haematology. 167(3). 366–375.
11.
Sharma, Sunil, Elisabeth G.E. de Vries, Jeffrey R. Infante, et al.. (2013). Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Investigational New Drugs. 32(1). 135–144.
12.
Bilic, Sanela, Douglas D. Leipold, William Mallet, et al.. (2013). American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates. mAbs. 5(1). 5–12.
13.
Byrd, John C., Thomas J. Kipps, Ian W. Flinn, et al.. (2012). Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leukemia & lymphoma. 53(11). 2136–2142.
14.
Bensinger, William, Richard T. Maziarz, Sundar Jagannath, et al.. (2012). A phase 1 study of lucatumumab, a fully human anti‐CD 40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. British Journal of Haematology. 159(1). 58–66.
15.
Brazeau, Gayle A., Susan M. Meyer, Edward M. Bednarczyk, et al.. (2009). Preparing Pharmacy Graduates for Traditional and Emerging Career Opportunities. American Journal of Pharmaceutical Education. 73(8). 157–157.
16.
Spencer, Andrew, Andrew W. Roberts, Nola Kennedy, et al.. (2008). Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. PubMed. 8(1). 2–2.
17.
Sharma, Shringi, Elisabeth G.E. de Vries, J. R. Infante, et al.. (2008). Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 3538–3538.
18.
Okusanya, Ólanrewaju O., Alan Forrest, Robin DiFrancesco, et al.. (2007). Compartmental Pharmacokinetic Analysis of Oral Amprenavir with Secondary Peaks. Antimicrobial Agents and Chemotherapy. 51(5). 1822–1826.
19.
Roboz, Gail J., Francis J. Giles, Alan F. List, et al.. (2006). Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 20(6). 952–957.
20.
Major, Pierre, James Berenson, Robert Vescio, et al.. (2005). The effect of zoledronic acid (Zol) dose and infusion rate on pharmacokinetics (PK), pharmacodynamics (PD), and renal function in patients (pts) with multiple myeloma (MM) or prostate cancer (PC) and bone metastases. Journal of Clinical Oncology. 23(16_suppl). 2079–2079.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Wichai Chinratanalab Breakdown of academic impact, for papers by Shih‐Feng Cho Breakdown of academic impact, for papers by Sherilyn A. Tuazon Breakdown of academic impact, for papers by Douglas W. Sborov Breakdown of academic impact, for papers by R N Sridhara Breakdown of academic impact, for papers by Gordon Moody Breakdown of academic impact, for papers by Caitlin Costello Breakdown of academic impact, for papers by Carolina Schinke Breakdown of academic impact, for papers by Rachel Kobos Breakdown of academic impact, for papers by Yvette C. Tanhehco